ir.accobrands.com
ACCO Brands - Investor Relations - Investor Relations Home
Receive Materials by Email. Information About Mead Consumer and Office Products Merger. ACCO Brands Corporation (NYSE: ACCO) is one of the world's largest suppliers of select categories of branded school, office and consumer products and print finishing solutions, with revenues of $1.7 billion. We market products in over 100 countries across the globe through our own sales force and distribution networks. Our industry-leading brands and products include AT-A-GLANCE. 160; 0.32. Minimum 20 minute delay.
ir.accretivehealth.com
Accretive Health, Inc. | Investor Relations | Investor Relations
Q2 2015 Accretive Health Inc Earnings Conference Call. 160;at 4:30 pm ET. Accretive Health is a leading provider of services and technology to healthcare providers. Our mission is to help our healthcare clients strengthen their financial stability and deliver better care at a more affordable cost to the communities they serve, increasing healthcare access for all. Our distinctive operating model that includes people, process, and sophisticated integrated technology helps our customers realize sus...CHICA...
ir.acelrx.com
AcelRx Pharmaceuticals, Inc : Investors
Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. 160;at 4:30 pm ET. Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. Monday, August 3, 2015 . 4:30 pm ET . Click here for webcast. Click here to add this event to your calendar. ACRX Corporate Presentation - 5/7/15. 160; 0.13. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results. Replication or redistribution of E...
ir.achillion.com
Investors | Achillion Pharmaceuticals
Presentations, Fact Sheet,. Life in New Haven. Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company’s mission to combat diseases by identifying and exploiting their unique vulnerabilities. Inspiring Science. Innovative Medicine. Mar 8, 2018. Achillion to Present at the Barclays Global Healthcare Conference. Feb 28, 2018. View all press releases ». Mar 15, 2018 at 11:15 AM ET. Barclays Global Healthcare Conference 2018.
ir.acorda.com
Acorda Therapeutics Inc - Investors
Investors span LayoutHomePageLayout Languageen-CA". Policy on Access to. Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Policy on Access to. March 26, 2018. Acorda Files Marketing Authorization Application for INBRIJA (levodopa inhalation powder). March 14, 2018. Acorda Rallies Parkinson’s Community in First-of-Its-Kind Initiative to Foster Better Conversations About Parkinson’s Symptoms.
ir.acsf.com
Investor Relations Home - Investor Relations - American Capital Senior Floating
Skip to main content. Dividend Reinvestment and Stock Purchase. Receive American Capital Senior Floating. 10-Q Q2 2015 (quarter ending June 30, 2015). 10-Q Q1 2015 (quarter ending March 31, 2015). American Capital Senior Floating, Ltd. Announces Monthly Cash Dividends of $0.097 per Share for August, September and October of 2015. American Capital Senior Floating Reports Net Investment Income of $0.32 per Share. American Capital Senior Floating, Ltd. Will Report Second Quarter 2015 Results on August 3.
ir.actiniumpharma.com
Investor Relations :: Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference. Jan 10, 2017. Ended Sep 30, 2016. Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. New York, NY 10016. 2469 E. Fort Union Blvd. Salt Lake City, UT 84121. Receive the latest news, events and updates! 2017 Actinium Pharmaceuticals, Inc.
ir.activepower.com
Investor Overview - Active Power Investors Relations
150 kVA â 1200 kVA). 750 kVA â 3 MVA). Our products are built on our elegant, field proven flywheel technology that delivers an unmatched combination of power density, reliability, and total cost of ownership. This combination enables our customers to achieve their availability, reliability, and budget goals. Q2 2015 Earnings Release. Q2 2015 Active Power, Inc. Earnings Conference Call. Q2 2015 â 10-Q. 160; 0.08. Data as of 08/07/15Â 4:00 pm ET. Minimum 20 minute delay. Active Power to Present at 43rd An...
ir.activisionblizzard.com
Activision Blizzard, Inc. | Investor Relations
Activision Blizzard, Inc. is the largest and most profitable western interactive entertainment publishing company. It develops and publishes some of the most successful and beloved entertainment franchises in any medium, including. Call of Duty,. Call of Duty Online,. Aug 6, 2015. Hellfire Rains on Azeroth in World of Warcraft: Legion™. Aug 5, 2015. Activision Brings Strongest Ever Line-up to Gamescom 2015. Aug 4, 2015 at 1:30 PM PT. Activision Blizzard Second Quarter Calendar 2015 Results Conference Call.
ir.adamaspharma.com
Investors - Adamas Pharmaceuticals, Inc.
Scientific and Clinical Advisors. Please email ir@adamaspharma.com. For assistance with Investor Relations questions. Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. 4:00 PM ET on Aug 14, 2015.
ir.adamispharmaceuticals.com
Overview | Investors | Adamis
11682 El Camino Real, Suite # 300. San Diego, CA 92130. Investor Relations and Media Contact:. Director, Investor Relations and Corporate Communications. First American Stock Transfer. 4747 N. 7th Street, Suite # 170. Phoenix, AZ 85014. Mayer Hoffman McCann P.C. Http:/ www.mhm-pc.com. Weintraub Tobin Chediak Coleman Grodin. No Duty to Update. Data provided by Nasdaq. Minimum 15 minutes delayed. Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA.
